CrushSCI.com
Journal Selection & Manuscript Polishing Services
European Urology Oncology journal cover Medicine
Back to journal directory

Review Cycle Records

European Urology Oncology

Elsevier SCIE Non-OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
110.7Average days
111.5Median days
7Fastest days
308Longest days
2572025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

9 days

Re: Develtere D, Devos G. Metformin in prostate cancer: A negative repurposing story across the disease continuum. Urol Oncol 2026. https://doi.org/10.1016/j.euo.2026.04.014

AuthorsCameron E. Alexander; Ashwin Sachdeva; Noel W. Clarke

AffiliationsDepartment of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Genitourinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UK

Source PDF DOI Publisher page
178 days

Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis

AuthorsAleksander Ślusarczyk; Marco Moschini; Wojciech Krajewski; Pietro Scilipoti; Roberto Contieri; Francesco Claps; José Daniel Subiela; Laura S. Mertens; Keiichiro Mori; Jorge Caño Velasco; Francesco Soria; Elisabeth Grobet-Jeandin; Karl Tully; Karolina Garbas; Pedro Del Olmo Durán; Renee A.G. Lijnen; Giorgia Fertitta; Maxence Reynard; Olga Katzendorn; Alfonso Lafuente Puentedura; Mattia Longoni; David D’Andrea; Francesco Del Giudice; Andrea Gallioli; Ekaterina Laukhtina; Gautier Marcq; Andrea Mari; Luca Afferi; Simone Albisinni; Antonio Amodeo; Stephen A. Boorjian; Alberto Briganti; Francesco Montorsi; Shahrokh F. Shariat; Paolo Gontero; Piotr Radziszewski; Benjamin Pradere

AffiliationsDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland; Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Department of Urology and Oncologic Urology, Wrocław Medical University, Wroclaw, Poland; Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy; Oncological Urology, Veneto Institute of Oncology, Padua, Italy; Department of Urology, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Clínica Universidad de Navarra, Cancer Center, Pamplona, Spain; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; Division of Urology, Geneva University Hospitals, Geneva, Switzerland; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany; Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France; Department of Urology, Gregorio Marañón University Hospital, Madrid, Spain; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Maternal, Infant, and Urologic Sciences, “Sapienza” University of Rome, Policlinico Umberto I Hospital, Rome, Italy; Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain; Department of Urology, Claude Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Department of Urology, University of Florence, Careggi Hospital, Florence, Italy; Department of Urology, Aarau Kantonsspital, Aarau, Switzerland; Urology Unit, Department of Surgical Sciences, Policlinico Tor Vergata, Tor Vergata University, Roma, Italy; Department of Urology, Mayo Clinic, Rochester, MN, USA; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Semmelweis University, Budapest, Hungary

Source PDF DOI Publisher page
61 days

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer

AuthorsQuentin Josset; Audrey Blanc-Lapierre; Grégoire Pigne; Lysian Cartier; David Pasquier; Philippe Ronchin; Guillaume Bera; Ali Hasbini; Benjamin Schipman; Jonathan Khalifa; Paul Sargos; Magali Quivrin; Ulrike Schick; Frédéric Mallet; Cecile Laude; Clotilde Morand; Geneviève Loos; Loig Vaugier; Ke Zhou; Nathalie Mesgouez-Nebout; Stéphane Supiot

AffiliationsDepartment of Radiation Oncology, Institut de Cancérologie de l’Ouest, Nantes, Angers, France; Department of Biostatistics, Institut de Cancérologie de l’Ouest, Boulevard J. Monod, Nantes, St-Herblain, France; Department of Radiation Oncology, Institut de Cancérologie de la Loire, St-Priest-en-Jarez, France; Department of Radiation Oncology, Institut Sainte Catherine, Avignon, France; Academic Radiation Oncology Department, Centre Oscar Lambret, Lille, France; Department of Radiation Oncology, Centre Azuréen de Cancérologie, Mougins, France; Department of Radiation Oncology, Centre Hospitalier (CH) Bretagne Sud, Lorient, France; Department of Radiation Oncology, Clinique Pasteur, Brest, France; Department of Radiation Oncology, Institut de Cancérologie de Bourgogne, Dijon, France; Department of Radiation Oncology, Institut Claudius Regaud, Toulouse, France; Department of Radiation Oncology, Institut Bergonie, Bordeaux, France; Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France; Department of Radiation Oncology, Centre Hospitalier Régional Universitaire (CHRU) Morvan, Brest, France; Department of Radiation Oncology, Institut de Cancer Courlancy, Reims, France; Department of Radiation Oncology, Centre Léon Bérard, Lyon, France; Department of Radiation Oncology, Centre Hospitalier Départemental (CHD) Vendée, La Roche-sur-Yon, France; Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France; Centre National de la Recherche Scientifique (CNRS) Unité en Sciences Biologiques et Biotechnologiques (US2B), Nantes University, Nantes, France

Source PDF DOI Publisher page
308 days

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study

AuthorsPhilipp Cornelius Mandel; Mike Wenzel; María Natalia Gandur Quiroga; Maria T. Bourlon; Felix Chun; Zin W. Myint; Laura Bernal; Ray Manneh Kopp; Maria José Juan Fita; Thomas Büttner; Ondrej Fiala; Haoran Li; Martin Bögemann; Tomas Buchler; Diana Matthews; Alessandro Rizzo; Francesco Ciccimarra; Fernando Sabino Marques Monteiro; Andrey Soares; Francesco Massari; Thomas Steuber; Matteo Santoni

AffiliationsDepartment of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; Martini-Klinik Prostate Cancer Center & Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA; Clínica Universitaria Colombia Sanitas - Clínica Marly, Colombia; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia; Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany; Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA; Department of Urology, University Hospital Münster, Münster, Germany; West German Cancer Center, Münster, Germany; Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic; Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, Wales, UK; S.S.D. c.O.r.o. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; Hospital Sírio-Libanês, Brasília, DF, Brazil; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Medical Oncology Unit, Macerata Hospital, Macerata, Italy

Source PDF DOI Publisher page
139 days

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy

AuthorsAndrea Necchi; Giorgio Brembilla; Karissa Whiting; Yuki Arita; Oguz Akin; Aditya Apte; Muhammad Awais; Alfonso Lema-Dopico; Ramesh Paudyal; Michele Cosenza; Brigida Anna Maiorano; Valentina Tateo; Antonio Cigliola; Chiara Mercinelli; Francesco De Cobelli; Marinela Capanu; Amita Shukla-Dave; Lawrence H. Schwartz

AffiliationsDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, Vita-Salute San Raffaele University, Milan, Italy; Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA

Source PDF DOI Publisher page
146 days

Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus

AuthorsPaolo Gontero; Richard Perry; Daisy Bridge; Diane Dalila Delattre; Sebastian Vosgerau; Robin Wyn; Medi Stone; Marek Babjuk

AffiliationsDepartment of Urology, University of Turin School of Medicine, Italy; Adelphi Values PROVE, Bollington, UK; Ferring Pharmaceuticals, Kastrup, Denmark; Department of Urology, 2nd Faculty of Medicine, Charles University, University Hospital Motol and Homolka, Prague, Czech Republic

Source PDF DOI Publisher page
25 days

EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer

AuthorsHongda Zhao; Jinyue Liao; Ho Vincy Wing Sze; Kang Liu; Xuan Chen; Hongwei Wu; Qiaoxiu Wang; Jiahui Hu; Peter Ho Yin Luk; Peter Ka-Fung Chiu; Chi Fai Ng; Dinglan Wu; Jeremy Yuen-Chun Teoh

AffiliationsS.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China; Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China; Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China; Department of Urology, Medical University of Vienna, Vienna, Austria

Source PDF DOI Publisher page
84 days

Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes

AuthorsArighno Das; Elizabeth E. Ellis; Pheroze Tamboli; Priya Rao; Aradhana M. Venkatesan; Zhouxuan Li; Wei Qiao; Surena F. Matin; Jose A. Karam; Brittney H. Cotta

AffiliationsDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Source PDF DOI Publisher page
7 days

Re: Michael Baboudjian, Alessandro Uleri, Julien Anract, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.006

AuthorsAlexander Light; Hashim U. Ahmed; Taimur T. Shah

AffiliationsImperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK

Source PDF DOI Publisher page
150 days

DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer

AuthorsSøren Klingenberg; Maria S. Lindgren; Jakob K. Jakobsen; Jørgen B. Jensen; Pernille S. Kingo

AffiliationsDepartment of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark; Department of Urology, Aalborg University Hospital, Aalborg, Denmark

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.